Beneficial effect of triple treatment plus immunoglobulin in experimental nephrotic syndrome

Pediatric Nephrology

Volumn 24, Issue 6, 2009, Pages 1173-1180

  Akman, Sema ^a   Kalay, Salih ^a   Akkaya, Bahar ^a   Koyun, Mustafa ^a   Akbaş, Halide ^a   Baysal, Yunus Emre ^a   Guven, Ayfer Gur ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Adriamycin induced nephrotic syndrome; Angiotensin I converting enzyme inhibitors; Angiotensin II receptor antagonist; High dose immunoglobulin; Statin

Indexed keywords

CREATININE; ENALAPRIL; ENAPRIL; IMMUNOGLOBULIN G; LOSARTAN POTASSIUM; PROTEIN; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG EFFECT; DRUG MEGADOSE; GLOMERULOSCLEROSIS; KIDNEY FIBROSIS; KIDNEY FUNCTION; MALE; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CREATININE; DRUG THERAPY, COMBINATION; ENALAPRIL; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; LOSARTAN; MALE; NEPHROTIC SYNDROME; PROTEINURIA; RATS; RATS, WISTAR; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 67650293137     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-009-1117-x     Document Type: Article

References (47)

1. Grond J, Weening JJ, Elema JD (1984) Glomerular sclerosis in nephrotic rats. Comparison of the long-term effects of adriamycin and aminonucleoside. Lab Invest 51:277-285
2. Sakemi T, Ohtsuka N, Tomiyoshi Y, Morito F (1996) Sex difference in progression of adriamycin-induced nephropathy in rats. Am J Nephrol 16:540-547
3. Okasora T, Takikawa T, Utsunomiya Y, Senoh I, Hayashibara H, Shiraki K, Kasagi T, Shimizu F (1992) Suppressive effect of superoxide dismutase on adriamycin nephropathy. Nephron 60:199-203
4. Van den Branden C, Ceyssens B, De Craemer D, Pauwels M, Vanden Houte K, De Bleser P, Hellemans K, Geerts A, Verbeelen D (2000) Renal antioxidant enzymes and fibrosis-related markers in the rat adriamycin model. Nephron 86:167-175
5. Ozen S, Usta Y, Sahin-Erdemli I, Orhan D, Gumusel B, Yang B, Gursoy Y, Tulunay O, Dalkara T, Bakkaloglu A, El-Nahas M (2001) Association of nitric oxide production and apoptosis in a model of experimental nephropathy. Nephrol Dial Transplant 16:32-38
6. Bricio T, Molina A, Mampaso F (1992) Effect of anti-interleukin-1 administration to rats with adriamycin-induced nephrosis. APMIS 100:401-407
7. Abbate M, Zoja C, Rottoli D, Corna D, Perico N, Bertani T, Remuzzi G (1999) Antiproteinuric therapy while preventing the abnormal protein traffic in proximal tubule abrogates protein and complement-dependent interstitial inflammation in experimental renal disease. J Am Soc Nephrol 10:804-813
8. Zoja C, Donadelli R, Corna D, Testa D, Facchinetti D, Maffi R, Luzzana E, Colosio V, Bertani T, Remuzzi G (1997) The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. Am J Kidney Dis 29:254-264
9. Perico N, Amuchastegui SC, Colosio V, Sonzogni G, Bertani T, Remuzzi G (1994) Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 5:1139-1146
10. Taal MW, Brenner BM (2000) Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 57:1803-1817
11. Kim SI, Kim HJ, Han DC, Lee HB (2000) Effect of lovastatin on small GTP binding proteins and on TGF-b1 and fibronectin expression. Kidney Int 58:S88-S92
12. Hundt M, Manger K, Dorner T, Grimbacher B, Kalden P, Rascu A, Weber D, Burmester GR, Peter HH, Kladen JR, Schmidt RE (2000) Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology 39:1301-1302
13. Yokoyama H, Goshima S, Wada T, Takaeda M, Furuichi K, Kobayashi K, Kida H (1999) The short- and long-term outcomes of membranous nephropathy treated with intravenous immune globulin therapy. Kanazawa study group for renal diseases and hypertension. Nephrol Dial Transplant 14:2379-2386
14. Rostoker G, Desvaux-Belghiti D, Pilatte Y, Petit-Phar M, Philippon C, Deforges L, Terzidis H, Intrator L, André C, Adnot S, Bonin P, Bierling P, Rémy P, Lagrue G, Lang P, Weil B (1994) High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura. Ann Intern Med 120:476-484
15. Jungi TW, Brcic M, Kuhnert P, Spycher MO, Li F, Nydegger UE (1990) Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. Clin Exp Immunol 82:163-169
16. Abe Y, Horiuchi A, Miyake M, Kimura S (1994) Anti-cytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 139:5-19
17. Andersson UG, Bjork L, Skansén-Saphir U, Andersson JP (1993) Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 79:211-216
18. Basta M, Fries LF, Frank MM (1991) High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 77:376-380
19. Dietrich G, Kaveri SV, Kazatchkine MD (1992) Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol 62:S73-S81
20. Blanchette VS, Kirby MA, Turner C (1992) Role of intravenous immunoglobulin G in autoimmune hematologic disorders. Semin Hematol 29:72-82
21. Toungouz M, Denys CH, De Groote D, Dupont E (1995) In vitro inhibition of tumour necrosis factor-alpha and interleukin-6 production by intravenous immunoglobulins. Br J Haematol 89:698-703
22. Shalhoub RJ (1974) Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet 2:556-560
23. Yap HK, Cheung W, Murugasu B, Sim SK, Seah CC, Jordan SC (1999) Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: Evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 10:529-537
24. Stefanoviç V, Goluboviç E, Mitic-Zlatkovic M, Vlahovic P, Jovanovic O, Bogdanovic R (1998) Interleukin-12 and interferon-gamma production in childhood idiopathic nephrotic syndrome. Pediatr Nephrol 12:463-466
25. Sahali D, Pawlak A, Le Gouvello S, Lang P, Valanciute A, Remy P, Loirat C, Niaudet P, Bensman A, Guellaen G (2001) Transcriptional and post-transcriptional alterations of IκBα in active minimal-change nephrotic syndrome. J Am Soc Nephrol 12:1648-1658
26. Cao C, Lu S, Dong C, Zhao R (2001) Abnormal DNA-binding of transcription factors in minimal-change nephrotic syndrome. Pediatr Nephrol 16:790-795
27. Erisir S, Akbas H, Koyun M, Akman S (2006) The efficiency of intraperitoneal high-dose immunoglobulin in experimental nephrotic syndrome. Pediatr Nephrol 21:39-45
28. Okuda S, Oh Y, Tsuruda H, Onoyama K, Fujimi S, Fujishima M (1986) Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 29:502-510
29. Diamond JR, Anderson S (1990) Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition. Am J Pathol 137:1323-1332
30. Attia DM, Feron O, Goldschmeding R, Radermakers LH, Vaziri ND, Boer P, Balligand JL, Koomans HA, Joles JA (2004) Hypercholesterolemia in rats induces podocyte stress and decreases renal cortical nitric oxide synthesis via an angiotensin II type 1 receptor-sensitive mechanism. J Am Soc Nephrol 15:949-957
31. Zoja C, Corna D, Rottoli D, Cattaneo D, Zanchi C, Tomasoni S, Abbate M, Remuzzi G (2002) Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney Int 61:1635-1645
32. Raij L, Azar S, Keane W (1984) Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26:137-143
33. Zoja C, Benigni A, Camozzi D, Corna D, Longaretti L, Todeschini M, Remuzzi G (2003) Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. Kidney Int 64:857-863
34. Coa Z, Cooper ME, Wu LL, Cox AJ, Jandeleit-Dahm K, Kelly DJ, Gilbert RE (2000) Blockade of the renin-angiotensin and endothelin systems on progressive renal injury. Hypertension 36:561-568
35. Wilkinson-Berka JL, Gibbs NJ, Cooper ME, Skinner SL, Kelly DJ (2001) Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant 16:1343-1349
36. Bos H, Henning RH, De Boer E, Tiebosch AT, De Jong PE, De Zeeuw D, Navis G (2002) Addition of AT1 blocker fails to overcome resistance to ACE inhibition in adriamycin nephrosis. Kidney Int 61:473-480
37. Zoja C, Corna D, Camozzi D, Cattaneo D, Rottoli D, Batani C, Zanchi C, Abbate M, Remuzzi G (2002) How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J Am Soc Nephrol 13:2898-2908
38. Branton MH, Kopp JB (1999) TGF-b and fibrosis. Microbes Infect 1:1349-1365
39. Khalil A, Tullus K, Bakhiet M, Burman LG, Jaremko G, Brauner A (2000) Angiotensin II type 1 receptor antagonist (losartan) down-regulates transforming growth factor-beta in experimental acute pyelonephritis. J Urol 164:186-191
40. Goumenos DS, Tsamandas AC, Oldroyd S, Sotsiou F, Tsakas S, Petropoulou C, Bonikos D, El Nahas AM, Vlachojannis JG (2001) Transforming growth factor-b1 in kidney and urine of patients with glomerular disease and proteinuria. Nephron 87:240-248
41. Taniguchi Y, Yorioka N, Masaki T, Yamashita K, Ito T, Ueda H, Yamakido M (2000) Role of transforming growth factor beta 1 in glomerulonephritis. J Int Med Res 25:71-80
42. Wasilewska AM, Zoch-Zwierz WM (2004) Transforming growth factor-β1 in nephrotic syndrome treated with cyclosporine and ACE inhibitors. Pediatr Nephrol 19:1349-1353
43. Zhang W, Li Q, Wang L, Yang X (2008) Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats. Pediatr Nephrol 23:2185-2194
44. Adamczak M, Gross ML, Amnn K, Ritz E (2004) Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. J Am Soc Nephrol 15:3063-3072
45. Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I (1998) Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53:937-944
46. Benchetrit S, Golan E, Podjarny E, Green J, Rashid G, Bernheim J, Hershkovitz R, Bernheim J (2001) Low molecular weight heparin reduces proteinuria and modulates glomerular TNF alpha production in the early phase of adriamycin nephropathy. Nephron 87:155-160
47. Zima T, Tesar V, Stipek S, Crkovska J, Poledne R, Teminova J, Platenik J, Rychlik I, Merta M, Nemecek K (1997) The influence of cyclosporine on lipid peroxidation and superoxide dismutase in adriamycin nephropathy in rats. Nephron 75:464-468